✦ LIBER ✦

Efficacy and Safety of Changing From Cyclosporine C0 to C2 Monitoring in Stable Recipients Following Renal Transplantation: A Prospective Cohort Study

✍ Scribed by Y. Zhang; X.D. Zhang; Y. Wang

Book ID: 113935214
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 158 KB
Volume: 43
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2011.08.105

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Feasibility of changing therapeutic cycl

Feasibility of changing therapeutic cyclosporine monitoring from C0 to C2 in stable renal recipients: narrower coefficient of variation with C2 monitoring

✍ S.-C. Chueh; C.-H. Liao; C.-J. Chang; M.-K. Lai 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 55 KB

12-month follow-up analysis of a multice

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

✍ Gary Levy; Gian Luca Grazi; Fernando Sanjuan; Youmin Wu; Ferdinand Mühlbacher; D 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

For complete listing of investigators and centers, see

Efficacy and Safety of Conversion from T

Efficacy and Safety of Conversion from Twice-daily to Once-daily Tacrolimus in a Large Cohort of Stable Kidney Transplant Recipients

✍ L. Guirado; C. Cantarell; A. Franco; E. G. Huertas; A. S. Fructuoso; A. Fernánde 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction

✍ M Cantarovich; H Ross; J Arizon; J Orus; L Straatman; J Howlett; E Lage; M Cresp 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

✍ H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB